Caribou Biosciences, Inc. (NASDAQ:CRBU) Position Cut by Nelson Capital Management LLC

Nelson Capital Management LLC lessened its position in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 23.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 64,858 shares of the company’s stock after selling 20,162 shares during the period. Nelson Capital Management LLC’s holdings in Caribou Biosciences were worth $103,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of CRBU. Erste Asset Management GmbH bought a new stake in shares of Caribou Biosciences during the third quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. increased its position in Caribou Biosciences by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock valued at $34,000 after acquiring an additional 6,768 shares during the period. Intech Investment Management LLC acquired a new position in Caribou Biosciences during the 3rd quarter worth $43,000. Thrive Wealth Management LLC bought a new position in shares of Caribou Biosciences in the fourth quarter worth $51,000. Finally, Barclays PLC increased its holdings in shares of Caribou Biosciences by 122.4% during the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock valued at $255,000 after purchasing an additional 71,463 shares during the period. 77.51% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CRBU has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Caribou Biosciences in a research note on Friday, November 15th. Citigroup dropped their target price on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Finally, Bank of America decreased their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Caribou Biosciences has a consensus rating of “Buy” and a consensus target price of $10.33.

Caribou Biosciences Stock Performance

Shares of NASDAQ:CRBU opened at $1.25 on Wednesday. Caribou Biosciences, Inc. has a 52 week low of $1.20 and a 52 week high of $8.33. The company has a market cap of $112.74 million, a PE ratio of -0.75 and a beta of 2.31. The firm has a 50 day simple moving average of $1.52 and a 200 day simple moving average of $1.86.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.